Skip to main content
Top
Published in: Medical Oncology 2/2008

Open Access 01-06-2008 | Original Paper

The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A

Authors: Jun Ishibashi, Kikuji Yamashita, Tatsuo Ishikawa, Hiroyoshi Hosokawa, Kaori Sumida, Masaru Nagayama, Seiichiro Kitamura

Published in: Medical Oncology | Issue 2/2008

Login to get access

Abstract

We developed a tissue culture incubator that can continuously irradiate cells with far-infrared radiation (FIR) of wavelengths between 4 and 20 μm with a peak of 7–12 μm, and found that FIR caused different inhibiting effects to five human cancer cell lines, namely A431 (vulva), HSC3 (tongue), Sa3 (gingiva), A549 (lung), and MCF7 (breast). Then, in order to make clear the control system for the effect of FIR, the gene expression concerned to the inhibition effect by FIR were analyzed. In consequence, basal expression level of HSP70A mRNA was higher in A431 and MCF7 cells than in the FIR-sensitive HSC3, Sa3, and A549 cells. Also, the over expression of HSP70 inhibited FIR-induced growth arrest in HSC3 cells, and an HSP70 siRNA inhibited the proliferation of A431 cells by irradiation with FIR. These results indicate that the effect of a body temperature range of FIR suppressing the proliferation of some cancer cells is controlled by the basal expression level of heat shock protein (HSP) 70A. This finding suggested that FIR should be very effective medical treatment for some cancer cells which have a low level of HSP70. Still more, if the level of HSP70 in any cancer of a patient was measured, the effect of medical treatment by FIR can be foreseen for the cancer.
Literature
1.
go back to reference Udagawa Y, Nagasawa H, Kiyokawa S. Inhibition by whole-body hyperthermia with far-infrared rays of the growth of spontaneous mammary tumours in mice. Anticancer Res 1999;19(5B):4125–30.PubMed Udagawa Y, Nagasawa H, Kiyokawa S. Inhibition by whole-body hyperthermia with far-infrared rays of the growth of spontaneous mammary tumours in mice. Anticancer Res 1999;19(5B):4125–30.PubMed
2.
go back to reference Udagawa Y, Nagasawa H. Effects of combined treatment with coffee cherry and whole-body hyperthermia on the growth of spontaneous mammary tumours in SHN mice. In vivo 2000;14(3):431–5.PubMed Udagawa Y, Nagasawa H. Effects of combined treatment with coffee cherry and whole-body hyperthermia on the growth of spontaneous mammary tumours in SHN mice. In vivo 2000;14(3):431–5.PubMed
3.
go back to reference Udagawa Y, Inada K, Nagasawa H. Inhibition by single whole-body hyperthermia with glucose administration of the growth of spontaneous mammary tumors in mice. Jpn J Hyperthermic Oncol 2000;16:229–36. Udagawa Y, Inada K, Nagasawa H. Inhibition by single whole-body hyperthermia with glucose administration of the growth of spontaneous mammary tumors in mice. Jpn J Hyperthermic Oncol 2000;16:229–36.
4.
go back to reference Nagasawa H, et al. Different schedules of whole-body hyperthermia with or without glucose for the inhibition of mammary tumors and uterine adenomyosis in SHN mice. Bull Sch Agr, Meiji Univ 2001;127:43–51. Nagasawa H, et al. Different schedules of whole-body hyperthermia with or without glucose for the inhibition of mammary tumors and uterine adenomyosis in SHN mice. Bull Sch Agr, Meiji Univ 2001;127:43–51.
5.
go back to reference Udagawa Y, Nagasawa H. Effects of far-infrared ray on reproduction, growth, behaviour and some physiological parameters in mice. In vivo 2000;14(2):321–6.PubMed Udagawa Y, Nagasawa H. Effects of far-infrared ray on reproduction, growth, behaviour and some physiological parameters in mice. In vivo 2000;14(2):321–6.PubMed
6.
go back to reference Nagasawa Y, Udagawa Y, Kiyokawa S. Evidence that irradiation of far-infrared rays inhibits mammary tumour growth in SHN mice. Anticancer Res 1999;19(3A):1797–800.PubMed Nagasawa Y, Udagawa Y, Kiyokawa S. Evidence that irradiation of far-infrared rays inhibits mammary tumour growth in SHN mice. Anticancer Res 1999;19(3A):1797–800.PubMed
7.
go back to reference Inoue S, Kabaya M. Biological activities caused by far-infrared radiation. Int J Biometeorol 1989;33(3):145–50.PubMedCrossRef Inoue S, Kabaya M. Biological activities caused by far-infrared radiation. Int J Biometeorol 1989;33(3):145–50.PubMedCrossRef
8.
go back to reference Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. Int J Biometeorol 1988;32(2):92–4.PubMedCrossRef Honda K, Inoue S. Sleep-enhancing effects of far-infrared radiation in rats. Int J Biometeorol 1988;32(2):92–4.PubMedCrossRef
9.
go back to reference Hosokawa H, et al. A new animal raiser : effect of limited infrared radiation on tumor growth of A431 cells. ITE Lett 2005;6(6):597–602. Hosokawa H, et al. A new animal raiser : effect of limited infrared radiation on tumor growth of A431 cells. ITE Lett 2005;6(6):597–602.
10.
go back to reference Teraoka F, Hamada Y, Takahashi J. Bamboo charcoal inhibits growth of HeLa cells in vitro. Dent Mater J 2004;23(4):633–7.PubMed Teraoka F, Hamada Y, Takahashi J. Bamboo charcoal inhibits growth of HeLa cells in vitro. Dent Mater J 2004;23(4):633–7.PubMed
11.
go back to reference Yamashita K, et al. Development of CO2 incubator with limited far-infrared radiation for activation of glucose metabolism. ITE Lett 2005;6(5):53–7. Yamashita K, et al. Development of CO2 incubator with limited far-infrared radiation for activation of glucose metabolism. ITE Lett 2005;6(5):53–7.
12.
go back to reference Wong HR, et al. Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Am J Physiol 1998;275(4 Pt 1):L836–41.PubMed Wong HR, et al. Increased expression of heat shock protein-70 protects A549 cells against hyperoxia. Am J Physiol 1998;275(4 Pt 1):L836–41.PubMed
13.
go back to reference Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 2000;926:122–5.PubMedCrossRef Nylandsted J, Brand K, Jaattela M. Heat shock protein 70 is required for the survival of cancer cells. Ann N Y Acad Sci 2000;926:122–5.PubMedCrossRef
14.
go back to reference Kaplan I, Kapp DS, Bagshaw MA. Secondary external-beam radiotherapy and hyperthermia for local recurrence after 125-iodine implantation in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1991;20(3):551–4.PubMed Kaplan I, Kapp DS, Bagshaw MA. Secondary external-beam radiotherapy and hyperthermia for local recurrence after 125-iodine implantation in adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1991;20(3):551–4.PubMed
15.
go back to reference Kaver I, Ware JL, Koontz WW Jr. The effect of hyperthermia on human prostatic carcinoma cell lines: evaluation in vitro. J Urol 1989;141(4):1025–7.PubMed Kaver I, Ware JL, Koontz WW Jr. The effect of hyperthermia on human prostatic carcinoma cell lines: evaluation in vitro. J Urol 1989;141(4):1025–7.PubMed
16.
go back to reference Paulus JA, et al. Heat shock protein response in a prostate tumor model to interstitial thermotherapy: implications for clinical treatment. Prostate 1993;23(3):263–70.PubMedCrossRef Paulus JA, et al. Heat shock protein response in a prostate tumor model to interstitial thermotherapy: implications for clinical treatment. Prostate 1993;23(3):263–70.PubMedCrossRef
17.
go back to reference Roigas J, et al. Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 1998;34(3):195–202.PubMedCrossRef Roigas J, et al. Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 1998;34(3):195–202.PubMedCrossRef
18.
19.
go back to reference Yerushalmi A. Localized, non-invasive deep microwave hyperthermia for the treatment of prostatic tumors: the first 5 years. Recent Results Cancer Res 1988;107:141–6.PubMed Yerushalmi A. Localized, non-invasive deep microwave hyperthermia for the treatment of prostatic tumors: the first 5 years. Recent Results Cancer Res 1988;107:141–6.PubMed
20.
go back to reference Bellmann K, et al. Heat shock protein hsp70 over expression confers resistance against nitric oxide. FEBS Lett 1996;391(1–2):185–8.PubMedCrossRef Bellmann K, et al. Heat shock protein hsp70 over expression confers resistance against nitric oxide. FEBS Lett 1996;391(1–2):185–8.PubMedCrossRef
21.
go back to reference Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998;80(2):183–201.PubMedCrossRef Kiang JG, Tsokos GC. Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 1998;80(2):183–201.PubMedCrossRef
22.
go back to reference Riabowol KT, Mizzen LA, Welch WJ. Heat shock is lethal to fibroblasts microinjected with antibodies against hsp70. Science 1988;242(4877):433–6.PubMedCrossRef Riabowol KT, Mizzen LA, Welch WJ. Heat shock is lethal to fibroblasts microinjected with antibodies against hsp70. Science 1988;242(4877):433–6.PubMedCrossRef
23.
go back to reference Vargas-Roig LM, et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 1997;21(5):441–51.PubMed Vargas-Roig LM, et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 1997;21(5):441–51.PubMed
Metadata
Title
The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A
Authors
Jun Ishibashi
Kikuji Yamashita
Tatsuo Ishikawa
Hiroyoshi Hosokawa
Kaori Sumida
Masaru Nagayama
Seiichiro Kitamura
Publication date
01-06-2008
Publisher
Humana Press Inc
Published in
Medical Oncology / Issue 2/2008
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-007-9020-4

Other articles of this Issue 2/2008

Medical Oncology 2/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.